IPO - Frazier Life Sciences Public Fund, L.P.

Form Type: SCHEDULE 13G

Filing Date: 2025-02-10

Corporate Action: Ipo

Type: New

Accession Number: 000141588925003423

Filing Summary: Frazier Life Sciences Public Fund, L.P. filed a Schedule 13G detailing its ownership of Common Stock of Maze Therapeutics, Inc. This report indicates that Frazier Life Sciences Public Fund, L.P. directly holds 2,376,617 shares, which constitutes approximately 5.4% of the company's outstanding shares, based on an expected total of 43,776,978 shares post-IPO. The document includes information on various affiliated funds under Frazier Life Sciences, such as the Frazier Life Sciences Public Overage Fund, Frazier Life Sciences X, and Frazier Life Sciences XI, which also hold shares in Maze Therapeutics. It mentions the shared voting and investment powers of the general partners of the funds, which include notable individuals such as Patrick J. Heron, James N. Topper, Albert Cha, and James Brush. The filing also reaffirms that the securities were not acquired for purposes of changing control of the issuer, emphasizing compliance with SEC regulations regarding disclosures.

Document Link: View Document